The Humanized Chimeric anti-ITGAL (Efalizumab Biosimilar) antibody has been validated for . It is suitable to detect ITGAL (Efalizumab Biosimilar) in samples from Human.
Catalog No. ABIN7597648
Quick Overview for Recombinant ITGAL (Efalizumab Biosimilar) antibody (ABIN7597648)
Target
ITGAL (Efalizumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Humanized
Clonality
Chimeric
Conjugate
This ITGAL (Efalizumab Biosimilar) antibody is un-conjugated
Application
Please inquire
Grade
Research Grade
Expression System
Mammalian cells
Purpose
Research Grade Efalizumab Biosimilar Antibody
Specificity
CD11A, Leukocyte function-associated molecule 1 alpha chain, Leukocyte adhesion glycoprotein LFA-1 alpha chain, LFA-1A, CD11 antigen-like family member A, CD11a, ITGAL, Integrin alpha-L
Purification
Protein A or G purified from cell culture supernatant.
Research Grade
Reactivity: Human
Host: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
0.01M PBS, pH 7.4.
Storage
4 °C,-20 °C,-80 °C
Storage Comment
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Expiry Date
12 months
Target
ITGAL (Efalizumab Biosimilar)
Alternative Name
Efalizumab Biosimilar
Target Type
Biosimilar
Background
CD11A, Leukocyte function-associated molecule 1 alpha chain, Leukocyte adhesion glycoprotein LFA-1 alpha chain, LFA-1A, CD11 antigen-like family member A, CD11a, ITGAL, Integrin alpha-L